BioSpace News Archive

VintaBio named Jennifer Kingsley as its first Chief Commercial Officer to develop and implement the company’s commercial strategy.

HALO Precision Diagnostics (“HALO”), the leader in early disease detection using precision diagnostics, today announced the appointment of John Craighead, Ph.D., as chief operating officer and chief financial officer.

Avertix Medical, Inc. and the Heart & Rhythm Institute of Trinity announced they have entered into an agreement to make the Guardian™ System, the first and only FDA-approved implantable heart attack detection and warning system, available to the Heart & Rhythm Institute of Trinity and its collaborative group of cardiologists who work across seven cardiology practices and serve seven hospitals in the area.

Procaps Group, S.A. announced the availability of a new white paper focused on gummy products, its revolutionary gummy technology, titled “Revolutionary Gummy Technology That Solves for The Supply Chain Constraints of Other Gummy Formats and Enhances Consumer Experience”.

Therapeutic Solutions International, Inc. (TSOI), reported today successfully generation of a quality control tested Master Cell Bank comprised of its JadiCell universal donor stem cell product. Prior to this, the Company relied on third party manufacturing, which carried significantly more costs as well as potential regulatory uncertainty.

Longeveron Inc. announced that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar.

On August 2, 2023 the New Jersey Board of Education adopted, in a narrow 6 to 5 vote, new rules framed as amendments promoting “Equity in Education.” A letter from the Association of American Physicians and Surgeons urges the board to immediately reverse the amendments.

Eyenovia, Inc. announced that it has entered into an agreement with Taiwan-based Formosa Pharmaceuticals whereby Eyenovia has acquired the exclusive U.S. Food and Drug Administration,

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into a licensing agreement with Eyenovia, Inc., whereby Eyenovia obtains exclusive U.S. rights for the commercialization of APP13007 for the treatment of inflammation and pain following ocular surgery.

AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, announced the appointment of Gavin Thurston, PhD, as a scientific advisor.